机构：[1]Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[2]Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[3]Department of Ophthalmology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[4]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Cancer drug resistance is a major obstacle to the effectiveness of chemoradiotherapy, targeted therapy, and immunotherapy. CRISPR/Cas9 library screening has emerged as a powerful genetic screening tool with significant potential to address this challenge. This review provides an overview of the development, methodologies, and applications of CRISPR/Cas9 library screening in the study of cancer drug resistance. We explore its role in elucidating resistance mechanisms, identifying novel anticancer targets, and optimizing treatment strategies. The use of in vivo single-cell CRISPR screens is also highlighted for their capacity to reveal T-cell regulatory networks in cancer immunotherapy. Challenges in clinical translation are discussed, including off-target effects, complexities in data interpretation, and model selection. Despite these obstacles, continuous technological advancements indicate a promising future for CRISPR/Cas9 library screening in overcoming cancer drug resistance.
基金：
Natural Science Foundation of China [82371060, 82304558]; Sichuan Province Innovative Talent Funding Project for Postdoctoral Fellows [BX202201]; Youth Fund of Natural Science Foundation of Sichuan Province; Sichuan Medical Association Medical Research Project [S23073]
第一作者机构：[1]Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China[4]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
共同第一作者：
通讯作者：
通讯机构：[1]Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China[2]Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences (2019RU026), Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China[3]Department of Ophthalmology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China[4]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
推荐引用方式(GB/T 7714)：
He Yu,Li Huan,Ju Xueming,et al.Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance[J].BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER.2024,1879(6):doi:10.1016/j.bbcan.2024.189212.
APA：
He, Yu,Li, Huan,Ju, Xueming&Gong, Bo.(2024).Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance.BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER,1879,(6)
MLA：
He, Yu,et al."Developing pioneering pharmacological strategies with CRISPR/Cas9 library screening to overcome cancer drug resistance".BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1879..6(2024)
：
医学